United Kingdom
Cannabis-based products for medical use
Thanks to deep scientific expertise, rigorous process management and quality control, EMMAC ensures MHRA medical-grade quality products with the full accreditation of relevant regulatory certifications for its manufacturing, distribution and supply processes.
Cutting-edge research
In partnership with leading European academic institutions including Imperial College London, EMMAC is at the forefront of research to deliver clinical data regarding the efficacy of medical cannabis for pain and the potential health benefits for patients.
End-to-end control
At EMMAC Life Sciences Group, we control the entire lifecycle of our medical cannabis – from cultivation and extraction to production and distribution.
People & expertise
EMMAC’s board and management team comprise of seasoned industry executives and consultants. Every member brings with them a wealth of knowledge and experience – from a range of scientific, medical, technical and FMCG backgrounds.
EMMAC announces pioneering research collaboration with Imperial College London
EMMAC Across Europe
EMMAC has developed unique supply and distribution partnerships across Europe to establish itself not only as a thought leader at the very forefront of research into the medical benefits of cannabis but also a European leader in the production and supply of medical cannabis, hemp and other derivative products.
Press Releases
EMMAC Life Sciences Group and Boiron selected for French Medical Cannabis trial
26 January 2021, London. EMMAC Life Sciences Group (“EMMAC” or the “Group” or the “Company”), Europe’s largest independent cannabis company,
EMMAC Life Sciences Group and Yooma Corp. Enter into Licensing Agreement for EMMAC Wellness Brands
Partnership to accelerate growth and drive new market entry, with a focus on Asia London (UK), and Toronto (Canada), January
EMMAC Life Sciences Group raises £15 million via successful issue of convertible notes
16 December 2020, London. EMMAC Life Sciences Group (“EMMAC” or the “Group” or the “Company”), Europe’s largest independent cannabis company,
EMMAC Life Sciences Group provides Corporate Update
04 November 2020, London. EMMAC Life Sciences Group (“EMMAC” or the “Group” or the “Company”), Europe’s largest independent cannabis company,
EMMAC Life Sciences Group announces UK manufacture of medical cannabis
16 October 2020, London. EMMAC Life Sciences Group (“EMMAC” or the “Group” or the “Company”), Europe’s largest independent cannabis company,
EMMAC secures GDP licence for Swiss pharmaceutical entity, EMMAC SAGL
18 August 2020, London. EMMAC Life Sciences Group, Europe’s largest independent cannabis company, is pleased to announce that EMMAC SAGL,
Stay informed
Fill in the form below to receive the latest news and developments in medical cannabis from EMMAC
